Is the Success of Cefazolin plus Ertapenem in Methicillin-Susceptible Staphylococcus aureus Bacteremia Based on Release of Interleukin-1 Beta?

Smelter, Dan; Hayney, Mary; Sakoulas, George; Rose, Warren

Smelter, Dan; Hayney, Mary; Sakoulas, George; Rose, Warren.

Afiliación

Smelter D; School of Pharmacy, University of Wisconsin-Madison, Madison, Wisconsin, USA.
Hayney M; School of Pharmacy, University of Wisconsin-Madison, Madison, Wisconsin, USA.
Sakoulas G; Division of Host-Microbe Systems & Therapeutics, Center for Immunity, Infection & Inflammation, University of California-San Diego School of Medicine, La Jolla, California, USA.
Rose W; School of Pharmacy, University of Wisconsin-Madison, Madison, Wisconsin, USA.

Antimicrob Agents Chemother ; 66(2): e0216621, 2022 02 15.

Article en En | MEDLINE | ID: mdl-34978891

Asunto(s)

Bacteriemia; Infecciones Estafilocócicas; Antibacterianos/farmacología; Antibacterianos/uso terapéutico; Bacteriemia/tratamiento farmacológico; Cefazolina/farmacología; Cefazolina/uso terapéutico; Ertapenem; Humanos; Interleucina-1beta; Meticilina/farmacología; Meticilina/uso terapéutico; Infecciones Estafilocócicas/tratamiento farmacológico; Staphylococcus aureus

Palabras clave

antimicrobial combinations; beta-lactams; immunology; in vitro; innate immunity

Texto completo

Imprimir

XML

PubMed Links

Buscar en Google

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Infecciones Estafilocócicas / Bacteriemia Límite: Humans Idioma: En Revista: Antimicrob Agents Chemother Año: 2022 Tipo del documento: Article País de afiliación: Estados Unidos

Texto completo

Imprimir

XML

PubMed Links

Buscar en Google